Two-Drug attack on Hard-to-Treat prostate cancer shows promise in early trial
NCT ID NCT07219147
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 29 times
Summary
This early-phase study tests whether combining a targeted radiation drug (177Lu-PSMA-617) with an immune cell therapy (Sipuleucel-T) works better than the radiation drug alone for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 30 men will take part. The goal is to see if the combination is safe and boosts the immune system's attack on cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.